Global research trends and prognostic risk factors for ST-segment elevation myocardial infarction: a bibliometric analysis from 2003 to 2025 Authors: Chen Shang, Yanru Wang, Qiuhong Chen, Juecen Wu, Yanguo Wang Published: 2026 ABSTRACT BackgroundPrognostic risk factors exert a critical influence on outcomes in patients with ST-segment elevation myocardial infarction (STEMI). However, global research trends and the primary determinants of research hotspots remain to be fully elucidated.MethodsA bibliometric analysis was conducted using CiteSpace and VOSviewer on 416 English-language publications retrieved from the Web of Science Core Collection database spanning 2003 to 2025. The analysis evaluated publication trends, contributions by country and institution, author productivity, journal impact, keyword co-occurrence, and citation networks.ResultsThe annual number of publications demonstrated a steady increase, particularly post-2016, reflecting a surge in scientific interest. China emerged as the leading contributor in terms of publication output. Author analysis identified 115 core authors, with Gierlotka, Marek and Polonski, Lech being the most prolific. The collaborative author network revealed five major research clusters. BMC Cardiovascular Disorders was identified as the primary source journal, while Circulation exhibited the highest citation impact. Keyword co-occurrence and burst detection analysis highlighted evolving research focuses, including risk stratification, primary angioplasty, inflammation, heart failure, and biomarker-based prognosis. Key risk factors influencing STEMI prognosis included advanced age, diabetes, hypertension, obesity, acute kidney injury, cardiogenic shock, and cardiac arrest. Current research trends focus on biomarkers and scoring systems; specifically, there is a trend toward investigating target biomarkers such as CXCL16 and miR-146a, while scoring systems still require tools specifically tailored for STEMI.ConclusionThe field of STEMI prognosis research is progressively evolving. Current research hotspots are concentrated on risk factors affecting STEMI prognosis, the investigation of targeted biomarkers, and the development of risk stratificat. Introduction ST-segment elevation myocardial infarction (STEMI), a severe manifestation of acute coronary syndrome, is characterized by total or near-total occlusion of a coronary artery, leading to sustained ischemia and subsequent necrosis of the corresponding myocardium [1]. In the United States, STEMI remains a significant healthcare burden, with approximately 750,000 cases reported annually [2, 3]. Despite a decline in overall incidence, the prevalence of modifiable risk factors among patients continues to rise [4]. In the current era of early reperfusion therapy and guideline-directed management, overall mortality from STEMI has decreased significantly. However, mortality remains as high as 50% in STEMI patients complicated by cardiac arrest [5]. Despite advances in therapeutic modalities, long-term prognosis for STEMI patients remains suboptimal. Studies indicate that the incidence of major adverse cardiac events (MACE) reaches 39.35% at the 1-year follow-up [6] and 26.7% at a median follow-up of 4.8 years [7] following percutaneous coronary intervention (PCI). These findings underscore the persistent challenges in improving long-term outcomes for STEMI patients, even in the context of modern treatment strategies. Bibliometrics is a quantitative analytical method used to evaluate scientific literature, revealing trends, hot topics, and the intellectual structure within a specific field [8]. This methodology enables researchers to rapidly grasp the research landscape, identify influential topics, and uncover gaps requiring further exploration. Currently, a substantial body of research exists regarding the prognosis of STEMI patients. A topic search in the Web of Science Core Collection database using the terms “STEMI” AND “Prognostic” retrieved 2,488 relevant publications, with approximately 150 papers published annually. This volume indicates a wealth of literature in the field of STEMI prognosis that warrants observation and integration. While bibliometric studies on STEMI exist, they have largely focused on single prognostic risk factors [9, 10]. Currently, there is a lack of comprehensive research integrating prognostic risk factors for STEMI patients. In this study, we employed bibliometric analysis to comprehensively evaluate global research on prognostic risk factors in STEMI patients. We used VOSviewer to create co-occurrence maps of keywords to identify the current research hotspots, and used Citespace to explore the temporal development and evolution patterns of keywords, thereby deducing the evolution process of STEMI research hotspots. Moreover, we combined the advantages of both software programs, extracting relevant data comprehensively and drawing charts such as publication volume, to better present the research results. Materials and methods Data source and acquisition All bibliometric data were obtained from the Web of Science Core Collection (WOSCC) database, which encompasses the Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Arts & Humanities Citation Index (AHCI), and Emerging Sources Citation Index (ESCI). The WOSCC database was selected due to its comprehensive coverage of high-quality, peer-reviewed publications and its suitability for bibliometric and scientometric analyses. A topic search was performed using the following index terms: “risk factor*”, “prognosis*”, “outcome*”, “ST-segment elevation myocardial infarction”, and “STEMI”. The search was restricted to publications published between 2000 and 2025. A total of 509 records were retrieved, and all eligible publications were downloaded on February 20, 2025. Search strategy All retrieved records were manually and independently screened against pre-defined inclusion and exclusion criteria to ensure the relevance and quality of the dataset. Only original research and review articles written in English were included to maintain consistency and reliability of the bibliometric indicators. Studies were required to be directly related to prognostic risk factors in patients with ST-segment elevation myocardial infarction. Articles such as meeting abstracts, early access publications, editorial materials, proceedings papers, database reviews, and letters were excluded to avoid non-peer-reviewed or incomplete content. Publications in non-English languages, including Russian, Portuguese, German, Spanish, and French, were also excluded. After removing duplicates and irrelevant studies, the remaining records constituted the final dataset for bibliometric analysis. This rigorous selection ensured that the analyzed literature accurately represented current research trends and scientific output in the field of STEMI prognosis. Bibliometric analysis tools The bibliometric and visualization analyses were conducted using two complementary software tools: VOSviewer (version 1.6.20; Leiden University, Leiden, the Netherlands) [11]. and CiteSpace (version 6.2.R3). VOSviewer, a widely used Java-based program, was applied to map and visualize bibliometric networks, including co-authorship, institutional collaboration, and keyword co-occurrenceQuantitative indicators such as the annual number of publications, total citations, average citations per publication (CPP), as well as distributions by countries, institutions, journals, and authors, were analyzed to assess research productivity and influence. CiteSpace was used to explore the intellectual structure and dynamic evolution of research in the field. This software enables identification of co-citation clusters, citation bursts, and keyword emergence, thereby highlighting pivotal studies and emerging trends. In this study, CiteSpace was employed to perform co-citation and keyword burst analyses to capture the current research status, evolution pathways, and frontiers of investigations into prognostic risk factors for STEMI. The combination of VOSviewer and CiteSpace allowed for a comprehensive, multi-dimensional bibliometric evaluation, integrating both quantitative performance indicators and qualitative visualization of the field’s knowledge structure and research hotspots. Results The initial database search yielded 509 publications. A flowchart illustrating the literature screening process is provided in Fig. 1 to enhance clarity. Ultimately, 416 publications met the inclusion criteria and were included in the bibliometric analysis. After the first round of screening, which retained only “articles” and “reviews,” 8 conference abstracts, 4 pre-published articles, 4 editorials, 3 conference papers, 1 database review, and 1 letter were excluded, leaving 488 publications. Restricting the language to English led to the exclusion of 15 non-English articles (7 in Russian, 3 in Portuguese, 2 in German, 2 in Spanish, and 1 in French), reducing the total to 473 publications. A further 56 studies unrelated to the research topic and 1 duplicate article were removed. Although the initial search retrieved two records from the year 2000 (with no relevant literature found for 2001 and 2002), these two articles were excluded as they did not meet the eligibility criteria. Consequently, the timeframe of the literature included in this study spans from 2003 to 2025.Fig. 1Flowchart of the Literature Screening Process. We conducted the literature screening in two steps. The first step excluded literature of unrelated types, and the second step excluded literature based on language and relevance to the topic Flowchart of the Literature Screening Process. We conducted the literature screening in two steps. The first step excluded literature of unrelated types, and the second step excluded literature based on language and relevance to the topic Publication trends As shown in Fig. 2, the number of publications on prognostic risk factors for STEMI has increased steadily over the past two decades. Annual publication output remained below 10 between 2003 and 2009, rose to an average of 15 between 2010 and 2015, and further increased to an average of 27 between 2016 and 2020. In the most recent period (2021–2024), the annual average reached 43 publications, with a peak of 51 in 2021. This upward trajectory indicates a growing global interest in the prognostic assessment and management of STEMI.Fig. 2The Publication Trend of Prognostic Risk Factors for STEMI. The vertical axis represents the number of publications, while the horizontal axis denotes the publication year. The height of each bar indicates the volume of publications, with taller bars signifying a greater number of articles The Publication Trend of Prognostic Risk Factors for STEMI. The vertical axis represents the number of publications, while the horizontal axis denotes the publication year. The height of each bar indicates the volume of publications, with taller bars signifying a greater number of articles Productive countries and institutions The 416 analyzed publications originated from 63 countries, 25 of which contributed more than five papers. China ranked first with 143 publications, followed by the United States [60], Italy [30], Germany [28], and Poland [28]. Sweden exhibited the highest average citation rate per article (62.45), followed by Australia (59.42), Canada (51.73), the United States (46.27), and Denmark (41.62). Detailed information on the top 20 most productive countries is presented in Table 1. Table 1The top 20 countries with the highest productivityCountryProductionTimes citedAverage citations per paperChina14310727.5United States60277646.27Italy30122940.97Germany2883029.64Poland2859121.11United Kingdom2271432.45Netherlands2147122.43Spain1836320.17Turkey1717810.47Canada1577651.73South Korea1429020.71Denmark1354141.62Australia1271359.42France1226822.33India12625.17Israel1227022.5Japan1119517.73Singapore1115814.36Sweden1168762.45Austria916618.44 Table 1The top 20 countries with the highest productivityCountryProductionTimes citedAverage citations per paperChina14310727.5United States60277646.27Italy30122940.97Germany2883029.64Poland2859121.11United Kingdom2271432.45Netherlands2147122.43Spain1836320.17Turkey1717810.47Canada1577651.73South Korea1429020.71Denmark1354141.62Australia1271359.42France1226822.33India12625.17Israel1227022.5Japan1119517.73Singapore1115814.36Sweden1168762.45Austria916618.44 The top 20 countries with the highest productivity An international collaboration network of 67 countries was constructed (Fig. 3). The analysis was performed using VOSviewer software with default parameters. In the visualization maps, a larger node size indicates a higher publication output, while a thicker link strength signifies a closer collaboration. The visualization highlights China, the United States, Poland, Italy, and Germany as having the largest nodes, indicating substantial research influence and collaboration intensity. The network forms seven clusters, among which the four largest are as follows: the red cluster is centered on France, with close collaborations with Denmark and Brazil; the green cluster is centered on the United States, closely connected to Poland and Canada; the blue cluster is centered on China, strongly linked to the Netherlands and Germany; and the yellow cluster is centered on the United Kingdom, collaborating most frequently with Singapore and South Korea.Fig. 3Visualization map of cooperation among countries. All countries are selected for collaboration analysis. Different colors represent different clusters, and the greater the collaboration strength, the thicker the line connecting them, the larger the number of national-issued documents, the larger the corresponding nodes Visualization map of cooperation among countries. All countries are selected for collaboration analysis. Different colors represent different clusters, and the greater the collaboration strength, the thicker the line connecting them, the larger the number of national-issued documents, the larger the corresponding nodes A total of 1,165 institutions contributed to the publications, with 33 producing five or more papers. Capital Medical University ranked first with 14 publications, followed by the Chinese Academy of Medical Sciences [12], the Cardiovascular Research Foundation [10], Anhui Medical University [9], and Columbia University [8]. The 20 most productive institutions are summarized in Table 2. Table 2The top 20 institution with the highest productivityInstitutionProductionTimes citedAverage citations per paperCapital Medical University14725.14Chinese Academy of Medical Sciences1213411.17Cardiovascular Research Foundation1055555.5Anhui Medical University9394.33Columbia University838448Duke University825031.25National University of Singapore814117.63Southern Medical University8678.38Chinese Academy of Medical Sciences & Peking Union Medical College7507.14Harvard Medical School713419.14Shanghai Jiao Tong University710615.14Swietokrzyskie Center of Cardiology716623.71University of Bologna6704117.33Duke Clinical Research Institute6661110.17University of Leipzig632454German Center for Cardiovascular Research616126.83Chonnam National University Hospital614924.83University of Copenhagen614023.33Peking Union Medical College66110.17Peking University6467.67 Table 2The top 20 institution with the highest productivityInstitutionProductionTimes citedAverage citations per paperCapital Medical University14725.14Chinese Academy of Medical Sciences1213411.17Cardiovascular Research Foundation1055555.5Anhui Medical University9394.33Columbia University838448Duke University825031.25National University of Singapore814117.63Southern Medical University8678.38Chinese Academy of Medical Sciences & Peking Union Medical College7507.14Harvard Medical School713419.14Shanghai Jiao Tong University710615.14Swietokrzyskie Center of Cardiology716623.71University of Bologna6704117.33Duke Clinical Research Institute6661110.17University of Leipzig632454German Center for Cardiovascular Research616126.83Chonnam National University Hospital614924.83University of Copenhagen614023.33Peking Union Medical College66110.17Peking University6467.67 The top 20 institution with the highest productivity Leading authors and co-authorship network A total of 3,321 authors contributed to the 416 publications. Among them, 19 authors had five or more papers. The most prolific authors were Gierlotka, Marek and Polonski, Lech, each with 10 publications, followed by Eitel, Ingo [9], Gasior, Mariusz [8], and Thiele, Holger [8]. The top 20 authors are listed in Table 3. Table 3The top 20 authors with the highest productivityAuthorProductionTimes citedAverage citations per paperGierlotka, Marek1022322.3Polonski, Lech1022322.3Eitel, Ingo938442.67Gasior, Mariusz819924.88Thiele, Holger837847.25Jeong, Myung Ho718025.71Desch, Steffen632854.67Granger, Christopher Bull657195.17Stone, Gregg Whitney618731.17Tan, Huay Cheem68514.17Chan, Mark Yan Yee57515Filipiak, Krzysztof J5479.4Gwon, Hyeon Cheol521042Loh, Poay Huan57014Mehran, Roxana514028Sadowski, Marcin511623.2Stiermaier, Thomas527054Yang, Yuejin5489.6Yu, Bo58216.4Eitel, Charlotte428471 Table 3The top 20 authors with the highest productivityAuthorProductionTimes citedAverage citations per paperGierlotka, Marek1022322.3Polonski, Lech1022322.3Eitel, Ingo938442.67Gasior, Mariusz819924.88Thiele, Holger837847.25Jeong, Myung Ho718025.71Desch, Steffen632854.67Granger, Christopher Bull657195.17Stone, Gregg Whitney618731.17Tan, Huay Cheem68514.17Chan, Mark Yan Yee57515Filipiak, Krzysztof J5479.4Gwon, Hyeon Cheol521042Loh, Poay Huan57014Mehran, Roxana514028Sadowski, Marcin511623.2Stiermaier, Thomas527054Yang, Yuejin5489.6Yu, Bo58216.4Eitel, Charlotte428471 The top 20 authors with the highest productivity According to Price’s Law, the minimum number of publications required to qualify as a core author in this field was calculated to be 2.39; therefore, authors with at least three publications were defined as core authors. A total of 115 core authors were identified, collectively contributing 165 articles, accounting for 39.66% of the total output. This proportion approaches the threshold proposed by Price, where the core authors contribute 50% of the total publications. Coupled with the finding that 19 authors have published more than five articles, this suggests that research on prognostic risk factors for STEMI is progressively maturing and that author collaborations are strengthening. It is anticipated that as an increasing number of researchers enter this field, more core authors will emerge, thereby fostering further development in this domain. Co-authorship analysis was performed for authors with more than four publications (Fig. 4). The analysis was performed using VOSviewer software with default parameters. In the visualization maps, a larger node size indicates a higher publication output, while a thicker link strength signifies a closer collaboration. Five distinct clusters were identified: Cluster 1, centered on Tan Huay Cheem, focuses on clinical research related to prognostic risk factors for STEMI; Cluster 2, led by Jeong Myung Ho, emphasizes studies on “gender” and “obesity”; Cluster 3, centered on Eitel Ingo, explores predictive scoring models; Cluster 4 is led by Gierlotka Marek; and Cluster 5, centered on Stone Gregg Whitney, focuses on interventional strategies and clinical outcomes.Fig. 4Visualization of research networks of authors. Authors with a publication count of 4 or more are selected for co - authorship network analysis. Identical colors mean these authors have previously collaborated, and the greater the collaboration strength, the thicker the line connecting them, the more articles an author publishes, the larger the corresponding node Visualization of research networks of authors. Authors with a publication count of 4 or more are selected for co - authorship network analysis. Identical colors mean these authors have previously collaborated, and the greater the collaboration strength, the thicker the line connecting them, the more articles an author publishes, the larger the corresponding node Analysis of journals The 416 papers were published across 191 journals. BMC Cardiovascular Disorders published the largest number (23 articles), followed by the American Journal of Cardiology and Frontiers in Cardiovascular Medicine (18 each), and Kardiologia Polska [14]. The top 20 journals by publication volume are presented in Table 4. Table 4The top 20 journals with the highest productivityJournalProductionTimes citedAverage citations per paperImpact factor 2024Open AccessJCRBMC Cardiovascular Disorders231888.172.1YesQ3American Journal of Cardiology1844324.612.3NoQ3Frontiers in Cardiovascular Medicine18965.332.8NoQ2Kardiologia Polska1414710.53.7YesQ3Coronary Artery Disease1112211.091.5NoQ4International Journal of Cardiology1138735.183.2NoQ1Journal of the American Heart Association1135832.554.6YesQ1Cureus Journal of Medical Science8121.51NoQ3Medicine8779.631.4YesQ2BMJ Open66310.52.4YesQ2Journal of the American College of Cardiology641969.8321.7NoQ1American Heart Journal516633.23.7NoQ1Chinese Medical Journal56112.27.5YesQ1Clinical Cardiology550102.4NoQ2European Heart Journal-Acute Cardiovascular Care519639.23.9NoQ1Herz56312.61.1NoQ4Journal of Cardiovascular Medicine57114.22.9NoQ2JACC-Cardiovascular Interventions42245611.7NoQ1Circulation43368435.6NoQ1Heart45714.255.1NoQ1JCR: Journal Citation Reports. Q1: Journals ranked in the top 25% of their subject category. These are the most influential and highly cited journals in their field. Q2: Journals ranked between 25% and 50% in their subject category. These journals are above average in terms of academic influence. Q3: Journals ranked between 50% and 75% in their subject category. These journals are below average in terms of academic influence. Q4: Journals ranked in the bottom 25% of their subject category. These are the least influential journals in their field Table 4The top 20 journals with the highest productivityJournalProductionTimes citedAverage citations per paperImpact factor 2024Open AccessJCRBMC Cardiovascular Disorders231888.172.1YesQ3American Journal of Cardiology1844324.612.3NoQ3Frontiers in Cardiovascular Medicine18965.332.8NoQ2Kardiologia Polska1414710.53.7YesQ3Coronary Artery Disease1112211.091.5NoQ4International Journal of Cardiology1138735.183.2NoQ1Journal of the American Heart Association1135832.554.6YesQ1Cureus Journal of Medical Science8121.51NoQ3Medicine8779.631.4YesQ2BMJ Open66310.52.4YesQ2Journal of the American College of Cardiology641969.8321.7NoQ1American Heart Journal516633.23.7NoQ1Chinese Medical Journal56112.27.5YesQ1Clinical Cardiology550102.4NoQ2European Heart Journal-Acute Cardiovascular Care519639.23.9NoQ1Herz56312.61.1NoQ4Journal of Cardiovascular Medicine57114.22.9NoQ2JACC-Cardiovascular Interventions42245611.7NoQ1Circulation43368435.6NoQ1Heart45714.255.1NoQ1JCR: Journal Citation Reports. Q1: Journals ranked in the top 25% of their subject category. These are the most influential and highly cited journals in their field. Q2: Journals ranked between 25% and 50% in their subject category. These journals are above average in terms of academic influence. Q3: Journals ranked between 50% and 75% in their subject category. These journals are below average in terms of academic influence. Q4: Journals ranked in the bottom 25% of their subject category. These are the least influential journals in their field The top 20 journals with the highest productivity JCR: Journal Citation Reports. Q1: Journals ranked in the top 25% of their subject category. These are the most influential and highly cited journals in their field. Q2: Journals ranked between 25% and 50% in their subject category. These journals are above average in terms of academic influence. Q3: Journals ranked between 50% and 75% in their subject category. These journals are below average in terms of academic influence. Q4: Journals ranked in the bottom 25% of their subject category. These are the least influential journals in their field Among these journals, Circulation had the highest average citation per article (84), followed by Journal of the American College of Cardiology (69.83), JACC: Cardiovascular Interventions [56], European Heart Journal: Acute Cardiovascular Care (39.2), and International Journal of Cardiology (35.18). All five belong to the Q1 category of the Journal Citation Reports (JCR), reflecting their high academic impact. Keyword analysis, co-occurrence, and burst detection A total of 1,091 unique keywords were identified across all publications. The most frequently occurring keywords were “STEMI” (174 occurrences), “risk factors” (156), “PCI” (143), “mortality” (134), “prognosis” (124), “outcomes” (116), “acute myocardial infarction” (97), “myocardial infarction” (94), “acute coronary syndromes (ACSs)” (88), “management” (64), “association” [57], and “gender” [45]. Seventy-two keywords with frequencies ≥ 10 were included in the co-occurrence analysis. The analysis was performed using VOSviewer software with default parameters. In the visualization maps, a larger node size indicates a higher publication output, while a thicker link strength signifies a closer collaboration. The resulting network (Fig. 5) comprised four clusters: the red cluster included “percutaneous coronary intervention,” “prognosis,” “predictors,” and “MACE”; the green cluster contained “risk factors,” “mortality,” “association,” and “diabetes mellitus”; the blue cluster featured “outcomes,” “management,” “intervention,” and “hospital mortality”; and the yellow cluster included “primary angioplasty,” “inflammation,” “risk assessment,” and “acute kidney injury.”Fig. 5Keyword co-occurrence network. Keywords appearing at least 10 times are selected for cluster analysis. Keywords of the same color tend to co - occur. The thicker the line, the higher the probability of co - occurrence, the more times a keyword appears, the larger the corresponding node will be Keyword co-occurrence network. Keywords appearing at least 10 times are selected for cluster analysis. Keywords of the same color tend to co - occur. The thicker the line, the higher the probability of co - occurrence, the more times a keyword appears, the larger the corresponding node will be Keyword burst analysis performed with CiteSpace is summarized in Table 5. The strongest bursts were observed for “outcomes” (burst intensity = 3.71), “diabetes mellitus” (3.61), “artery disease” (3.32), “intervention” (3.24), “major adverse cardiovascular events” (3.06), and “clinical trial” (3.03). The longest burst duration was found for “endothelial dysfunction” (2005–2016), followed by “diabetes mellitus” (2004–2013) and “artery disease” (2009–2017). The keyword “time-course” showed a burst from 2003 to 2011, while “primary angioplasty” exhibited a burst from 2013 to 2020. The temporal evolution analysis of keywords reveals shifts in research focus. We employed CiteSpace software to conduct a keyword burst detection analysis to explore these changes over the timeline. Using default parameters, a total of 25 burst keywords were identified (Table 5). Before 2010, studies mainly focused on basic mechanisms such as endothelial dysfunction and comorbidities; between 2010 and 2015, attention moved toward clinical evaluation and therapeutic optimization; from 2015 to 2020, focus expanded to risk stratification and integrated management; and in recent years, research has increasingly emphasized inflammation, heart failure, and precision-based risk scoring systems to enhance long-term outcomes in STEMI patients. Table 5Top 25 Keywords with the Strongest Citation BurstsLight blue represents the entire timeline, dark blue indicates the time period during which the keyword appears, and red highlights the time period of its burst Table 5Top 25 Keywords with the Strongest Citation BurstsLight blue represents the entire timeline, dark blue indicates the time period during which the keyword appears, and red highlights the time period of its burst Top 25 Keywords with the Strongest Citation Bursts Light blue represents the entire timeline, dark blue indicates the time period during which the keyword appears, and red highlights the time period of its burst Co-citation analysis Co-citation analysis was conducted to identify influential journals and articles within the field. Using VOSviewer, 10,537 cited references from 1,699 journals were analyzed. The most frequently cited journals were Circulation (1,284 citations), Journal of the American College of Cardiology (1,092), European Heart Journal (821), American Journal of Cardiology (663), and New England Journal of Medicine (504). The first three are leading cardiovascular journals (JCR Q1), while NEJM is a top-ranked multidisciplinary medical journal. Setting a threshold of 30 co-citations yielded 58 journals for mapping. The co-citation visualization (Fig. 6) revealed three clusters: the green cluster, representing journals focused on cardiovascular systems, imaging, and atherosclerosis; the blue cluster, encompassing sub-journals of general medical publications; and the red cluster, emphasizing cardiovascular disease treatment, clinical outcomes, emergency care, and nursing.Fig. 6Co-citation analysis of cited sources. A co - occurrence map of journals with cited frequencies over 30 helps identify key influential journals, reflect research hotspots, and reveal relationships between journals in the field. The lines represent the connections between journals, with thicker lines indicating closer connections. The size of the nodes represents the number of publications by the journals; larger nodes indicate more publications Co-citation analysis of cited sources. A co - occurrence map of journals with cited frequencies over 30 helps identify key influential journals, reflect research hotspots, and reveal relationships between journals in the field. The lines represent the connections between journals, with thicker lines indicating closer connections. The size of the nodes represents the number of publications by the journals; larger nodes indicate more publications Further article-level co-citation analysis identified 10 publications with ≥ 15 citations (Table 6). The three most frequently cited were major clinical practice guidelines: the 2017 ESC Guidelines for STEMI management (Ibanez, Borja et al., 69 citations), the 2012 ESC Guidelines for STEMI management (Steg, Gabriel Ph et al., 46 citations), and the 2013 ACCF/AHA STEMI Management Guideline Executive Summary (O’Gara, Patrick T et al., 42 citations). These highly cited documents underscore the pivotal role of evidence-based clinical recommendations in shaping STEMI prognosis research. Table 6The top 10 publications with the highest citationTitleYearsThe First AuthorJournalTimes cited2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)2018Ibanez, BorjaEuropean Heart Journal69ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation2012Steg, Gabriel PhEuropean Heart Journal462013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines2013O’Gara, Patrick TCirculation42TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy2000Morrow, Dacid ACirculation27Third universal definition of myocardial infarction2013Jaffe, Allan SClinical Biochemistry26Clinical end points in coronary stent trials: a case for standardized definitions2007Cutlip, Donald ECirculation22Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials2003Keeley, Ellen CLancet22Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study2004Yusuf, SalimLancet19Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients1967Kimball, John TThe American Journal Cardiology17The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings1985TIMI Study GroupThe New England Journal of Medicine17 Table 6The top 10 publications with the highest citationTitleYearsThe First AuthorJournalTimes cited2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)2018Ibanez, BorjaEuropean Heart Journal69ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation2012Steg, Gabriel PhEuropean Heart Journal462013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines2013O’Gara, Patrick TCirculation42TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy2000Morrow, Dacid ACirculation27Third universal definition of myocardial infarction2013Jaffe, Allan SClinical Biochemistry26Clinical end points in coronary stent trials: a case for standardized definitions2007Cutlip, Donald ECirculation22Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials2003Keeley, Ellen CLancet22Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study2004Yusuf, SalimLancet19Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients1967Kimball, John TThe American Journal Cardiology17The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings1985TIMI Study GroupThe New England Journal of Medicine17 The top 10 publications with the highest citation Cluster analysis of highly cited papers (≥ 6 citations) revealed six thematic groups (Fig. 7). The gray cluster focuses on global STEMI management guidelines and the prognostic value of classical risk factors. The purple cluster explores myocardial infarction characteristics in young patients, emphasizing angiographic features and long-term outcomes. The yellow cluster examines variations in acute coronary syndrome management and risk prediction, including TIMI score comparisons. The blue cluster addresses therapeutic strategies and their prognostic implications, particularly door-to-balloon time and the no-reflow phenomenon. The green cluster investigates gender-related disparities in STEMI, focusing on symptom presentation, treatment, and outcomes in women. Lastly, the red cluster centers on the pathological mechanisms underlying myocardial infarction and their influence on therapeutic efficacy and prognosis.Fig. 7co-citation analysis of cited reference .References with a co - citation frequency of 6 or more are selected for co - occurrence analysis. The larger the node, the higher the number of citations; the thicker the lines between nodes indicate a higher frequency of co-citation between two references co-citation analysis of cited reference .References with a co - citation frequency of 6 or more are selected for co - occurrence analysis. The larger the node, the higher the number of citations; the thicker the lines between nodes indicate a higher frequency of co-citation between two references Discussion Bibliometric analysis indicates that research on prognostic risk factors for STEMI was relatively limited prior to 2009. Although there is an extensive body of literature on STEMI within cardiovascular medicine, studies explicitly focusing on prognostic risk factors were scarce, reflecting the nascent stage of the field and limited initial attention. However, since 2010, scientific interest in this domain has grown steadily, driven by advancements in medical technology and an increasing emphasis on precision cardiovascular care. Among global contributors, China appears particularly enthusiastic about researching prognostic risk factors for STEMI. Research activity expanded rapidly starting in 2016; by 2021, China accounted for nearly half of global publications (23 articles), and by 2024, this figure exceeded 60% (26 articles). This rapid growth underscores the high level of engagement among Chinese scholars and the increasing number of researchers joining this field. Furthermore, this trend is likely linked to China’s rapid economic development and improved living standards, which have led to a greater medical prioritization of STEMI prognosis. In addition to China, several other countries—including Sweden, Australia, Canada, and the United States—have made significant contributions to this field. Swedish researchers have explored diverse aspects of STEMI prognosis, encompassing risk prediction, biomarker evaluation, therapeutic efficacy, and population-specific prognostic differences [12–15]. Australian studies have integrated multi-source data to assess cardiovascular risk factors and socioeconomic determinants, providing evidence-based recommendations for prevention and management [16–18]. In Canada, research has primarily focused on acute coronary syndromes and STEMI, emphasizing treatment strategies, prognosis, gender disparities, outcomes in younger patients, and data-driven models for assessing care quality [19–22]. Meanwhile, investigations in the United States have addressed the effects of comorbidities such as diabetes mellitus [23], acute kidney injury [24], and non-alcoholic fatty liver disease [25], as well as gender- and age-related outcome variations, offering insights into risk management and individualized prognostic assessment [26–29]. Collectively, these studies have deepened the global understanding of STEMI pathophysiology and outcomes, providing a scientific foundation for improving prevention, diagnosis, and treatment. Author analysis further revealed that Gierlotka, Marek, Polonski, Lech, and Gasior, Mariusz, all affiliated with the Silesian Centre for Heart Diseases in Poland, were among the most prolific contributors. Their research, published primarily between 2010 and 2013, investigated the prognostic implications of diabetes, chronic total occlusion, and invasive treatment strategies, as well as prognosis in specific subgroups such as women, elderly patients, and young adults [30–35]. Similarly, Eitel, Ingo, and Thiele, Holger from the German Center for Cardiovascular Research have made influential contributions to risk stratification since 2015. Their studies demonstrated that the left ventricular global function index provides incremental prognostic value beyond ejection fraction [36], introduced cardiac magnetic resonance (CMR)-based risk scores for STEMI [37], and emphasized major adverse cardiovascular events (MACE) as a key prognostic endpoint [38–41]. These contributions collectively offer valuable theoretical support and practical guidance for improving clinical decision-making and long-term patient management. Keyword co-occurrence analysis revealed multiple interconnected factors associated with the prognosis of STEMI. In the visualization map, a larger node size indicates a higher frequency of co-occurrence with STEMI, suggesting a research hotspot; however, this does not necessarily imply a direct clinical correlation with STEMI prognosis. Keywords with high co-occurrence frequencies included gender, age [42], smoking [43], hyperglycemia [44], hypertension [45], obesity [46], acute kidney injury [22], new-onset heart failure [47] chronic obstructive pulmonary disease [48], cardiogenic shock [49], cardiac arrest [50], and depression [51]. Among these, “gender” appeared as a prominent node, indicating it is a hotspot in prognostic research. Female gender has been extensively studied; although female STEMI patients are typically older and less likely to undergo PCI, gender itself is not an independent predictor of long-term mortality. Instead, comorbidities such as advanced age, hypertension, and diabetes largely explain the observed prognostic differences [33, 42, 52] Interestingly, other studies suggest that males may experience worse long-term outcomes following a first myocardial infarction [28]. Age is another hotspot predictor, associated with declining cardiovascular reserve, increased disease severity, and a higher burden of chronic illness. By extension, smoking, hyperglycemia, hypertension, and obesity are also relatively prominent factors in prognostic research. Smoking accelerates endothelial injury and atherosclerosis, increasing the risk of thrombosis, while hyperglycemia exacerbates endothelial dysfunction and plaque instability. Hypertension increases myocardial workload and aggravates ischemia, whereas obesity, often associated with metabolic syndrome, worsens prognosis through dyslipidemia and inflammation. Furthermore, acute kidney injury, new-onset heart failure, chronic obstructive pulmonary disease, cardiogenic shock, cardiac arrest, and depression further impair cardiac function and increase mortality risk. Collectively, these findings underscore the multifactorial nature of STEMI prognosis and highlight the necessity for comprehensive, individualized management. Recent research trends emphasize biomarkers and scoring systems as potential tools for enhancing the accuracy of STEMI prognosis. Several biomarkers have demonstrated promising predictive value. Historically, the LDL/HDL ratio has been utilized for diagnostic prediction in cardiology since the mid-to-late 20th century; an elevated ratio is considered an independent predictor of long-term coronary revascularization following PCI [53]. Regarding heart failure assessment, soluble ST2 (sST2) and Galectin-3 have gained recognition, with sST2 incorporated into guidelines in 2014 and Galectin-3 recommended in 2017 [54, 55]. CXCL16 and miR-146a represent emerging biomarkers currently in the research phase. Elevated plasma CXCL16 levels within 24 h of admission predict long-term mortality in patients with acute coronary syndrome [15] Similarly, increased miR-146a expression is associated with a higher incidence of major adverse cardiac events (MACE), potentially via inflammatory pathways involving S100A12 [56]. The potential of CXCL16 and miR-146a suggests that targeted biomarkers may represent a future direction for prognostic research, though their prognostic value and clinical applicability require validation in multicenter studies across diverse populations. Risk stratification models represent another focal point in STEMI prognostic research. Widely used scoring systems, such as TIMI, GRACE, SYNTAX, CHA2DS2-VASc, and C₂HEST scores, have demonstrated varying degrees of predictive accuracy [57]. The TIMI and GRACE scores were released around the year 2000. While they show comparable discrimination capabilities regarding in-hospital mortality, the TIMI score demonstrates superior calibration [58]. Proposed in 2005, the SYNTAX score has been a standard tool; however, the QFR-oriented residual SYNTAX score (Q-rFSS), introduced in 2011, has been proven superior to the traditional residual SYNTAX score in predicting MACE in patients undergoing PCI [59]. The CHA2DS2-VASc score, proposed in 2010, predicts in-hospital MACE, particularly in male patients [57]. Furthermore, combining the C2HEST score (proposed in 2020) with the platelet-to-albumin ratio improves the prediction of atrial fibrillation in elderly STEMI patients following PCI [60]. The sequential proposal and application of these models indicate that risk assessment tools for STEMI are continuously being enriched. However, since these models were not specifically designed for STEMI, their predictive performance varies across different cohorts. Consequently, developing and validating a scoring system specifically tailored for STEMI remains an urgent task to improve risk prediction, facilitate personalized treatment, and enhance clinical decision-making. Limitation Our study investigated the publication influence of authors, institutions, and countries through static data analysis. However, given the dynamic nature of scientific data, some authors and articles with generally low influence may exhibit high influence during specific periods. The lack of description regarding dynamic data constitutes one of the limitations of this study. Furthermore, while this study explored the association between certain topics and STEMI prognosis based on keyword co-occurrence frequency and influence, this merely reflects that these topics have received frequent attention in STEMI prognostic research, rather than constituting recommendations weighted by clinical evidence. We acknowledge this as a limitation and advise researchers to interpret these findings with caution. When we included literature, some studies matched our research in terms of topic, but due to unknown reasons, their data completeness was insufficient, which led to these studies being unable to be included in the analysis. This may cause bias in the research results. This is one of our limitations. Conclusion This study systematically analyzed the current research landscape and hotspots of prognostic risk factors for STEMI through bibliometric analysis, providing a quantitative foundation for constructing a knowledge map of the field. Research in this domain remains in a developmental stage. Future efforts should focus on strengthening clinical research to identify prognostic risk biomarkers for STEMI, with targeted biomarker prediction serving as a potential breakthrough. Currently, there is a lack of dedicated risk prediction scoring models for STEMI; therefore, the development of risk stratification models specifically tailored for STEMI patients is likely to become a hotspot in clinical research. Such advances will enhance the accuracy and reliability of risk prediction and support more effective clinical decision-making.